secwatch.observer — SEC 8-K summary
======================================

Issuer:     XWELL, Inc. (XWEL)
CIK:        0001410428
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-039221
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XWELL to file late 10-K due to impairment review; preliminary FY2022 revenue ~$56M
--------------------------------------------------------------------------------

- Plans to file Form 12b-25 for 15-day extension to assess non-cash impairment charge; 10-K expected by April 17, 2023.
- Preliminary FY2022 total revenue ~$56M: XpresSpa/Treat $15M, XpresCheck $32M, bio-surveillance $7M, HyperPointe $2M.
- Gross profit margin declined to ~22% from ~44% in 2021 due to lower testing volumes.
- G&A expenses ~$31M; second-half 2022 G&A ~$4M lower than first half reflecting cost savings.
- Cash and equivalents ~$42M; opened 5 XpresSpa locations in Istanbul, new spa at Philadelphia in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410428/000110465923039221/0001104659-23-039221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410428/000110465923039221/tm2311046d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer